- Home
- ANGO vs ALLO Comparison
ANGO vs ALLO Comparison
Compare ANGO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | ALLO |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 483.7M |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ANGO | ALLO |
|---|---|---|
| Price | $11.26 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $19.75 | $9.00 |
| AVG Volume (30 Days) | 921.2K | ★ 5.6M |
| Earning Date | 10-08-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $5.47 | N/A |
| Revenue Next Year | $5.10 | $255.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $9.39 | $1.04 |
| 52 Week High | $16.29 | $4.46 |
Technical Indicators
Market Signals| Indicator | ANGO | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 26.29 | 26.53 |
| Support Level | $10.21 | N/A |
| Resistance Level | $11.55 | $2.22 |
| Average True Range (ATR) | 0.83 | 0.07 |
| MACD | -0.36 | -0.01 |
| Stochastic Oscillator | 9.92 | 18.82 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).